Company Performance: DBV Technologies' clinical trial results, regulatory approvals (or rejections) for Viaskin Peanut, and overall financial health significantly influence its stock price. Positive developments generally lead to price increases, while negative news can cause declines.

Market Sentiment: General investor confidence in the biotechnology sector, as well as broader market trends (bullish or bearish), impacts DBV.PA. Positive market sentiment often supports higher valuations, whereas negative sentiment can pressure prices down.

Competition: The progress of competitors in developing treatments for peanut allergies and other food allergies affects investor perception of DBV's market potential. Successful products from competitors may negatively impact DBV.PA's price.

Regulatory Environment: Changes in regulations regarding drug development, approval processes, and reimbursement policies in key markets like the US and Europe can influence investor expectations and, therefore, DBV.PA's valuation.

Financial News: DBV Technologies' cash position, burn rate, and any announcements related to financing rounds (debt or equity) affect investor confidence and the perceived long-term viability of the company, impacting its stock price.